Who are HYML-122; cytarabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hepsera, Gemzar, VALACYCLOVIR, Cytarabine, Fludarabine (FLU), ACYC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hyml-122-cytarabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

HYML-122; cytarabine — Competitive Intelligence Brief

HYML-122; cytarabine (HYML-122; cytarabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: nucleoside analog. Area: Oncology.

phase 2 nucleoside analog DNA polymerase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HYML-122; cytarabine (HYML-122; cytarabine) — Tarapeutics Science Inc.. inhibits DNA polymerase

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HYML-122; cytarabine TARGET	HYML-122; cytarabine	Tarapeutics Science Inc.	phase 2	nucleoside analog	DNA polymerase
Hepsera	ADEFOVIR DIPIVOXIL	Gilead Sciences	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	2002-01-01
Gemzar	gemcitabine	Accord Hlthcare	marketed	Nucleoside Metabolic Inhibitor	DNA polymerase (alpha/delta/epsilon)	1996-01-01
VALACYCLOVIR	VALACYCLOVIR		marketed	Nucleoside analogue	Viral DNA polymerase	1995-01-01
Cytarabine	Cytarabine	Nippon Shinyaku Co., Ltd.	marketed	Antimetabolite	DNA polymerase	1969-01-01
Fludarabine (FLU)	Fludarabine (FLU)	Nanfang Hospital, Southern Medical University	marketed	Purine nucleoside analog	Ribonucleotide reductase, DNA polymerase
ACYC	ACYC	Ligand Pharms	marketed		Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (nucleoside analog class)

Atea Pharmaceuticals, Inc. · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Medivir · 1 drug in this class
Tarapeutics Science Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HYML-122; cytarabine — Competitive Intelligence Brief. https://druglandscape.com/ci/hyml-122-cytarabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab